Haemoctin Sdh (Human Coagulation Factor Viii)

Haemoctin Sdh is used to replace deficient factor VIII in individuals with bleeding disorders, helping to restore normal coagulation.

• Management of acute bleeding episodes in patients with hemophilia A.
• Peri‑operative supplementation for surgical or invasive procedures in factor VIII‑deficient patients.
• Prophylactic therapy to reduce the frequency of spontaneous bleeds in severe hemophilia A.
• Treatment of trauma‑related hemorrhage when factor VIII levels are low.
• Support during dental extractions or other minor procedures requiring hemostasis.

The safety profile of Haemoctin Sdh includes both frequently observed reactions and less common but serious events.

Common

• Mild infusion‑site erythema or swelling that resolves without intervention.
• Transient headache or dizziness occurring during or shortly after infusion.
• Low‑grade fever or chills lasting less than 24 hours.
• Nausea or mild abdominal discomfort that subsides with supportive care.

Serious

• Anaphylactic or severe allergic reactions requiring immediate medical attention.
• Development of inhibitory antibodies against factor VIII, reducing treatment effectiveness.
• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.
• Significant hemolysis or renal impairment observed in laboratory monitoring.

Clinicians should consider several precautionary measures before initiating Haemoctin Sdh therapy to ensure patient safety.

• Verify the diagnosis of factor VIII deficiency and baseline activity levels.
• Assess for a history of allergic reactions to plasma‑derived products.
• Screen for existing inhibitors to factor VIII using appropriate assays.
• Monitor vital signs and laboratory parameters during the first infusion.
• Adjust dosing in patients with renal or hepatic impairment as recommended.
• Counsel patients on signs of anaphylaxis and when to seek urgent care.

Haemoctin Sdh may interact with other medications or substances that affect coagulation or immune response.

Avoid

• Concurrent use of other factor VIII concentrates without specialist guidance.
• Administration of antifibrinolytic agents (e.g., tranexamic acid) in high doses without monitoring.

Use with caution

• Immunosuppressive therapies that could alter inhibitor development.
• Vaccines, particularly live attenuated vaccines, administered close to infusion times.
• Concomitant use of drugs that may increase thrombotic risk, such as estrogen‑containing oral contraceptives.